FDA Accepts Unicycive Therapeutics’ Resubmitted NDA
The FDA accepted the company’s resubmitted New Drug Application for oxylanthanum carbonate. Unicycive shares rose 5% to $4 in morning trade.
Unicycive Therapeutics shares advanced after the company reported that the Food and Drug Administration had accepted its resubmitted New Drug Application for oxylanthanum carbonate. The stock was 5% higher at $4 in morning trading. It has fallen 19% over the past 12 months. Oxylanthanum carbonate…